Barcelona

• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie … Ended
  2024-511164-92-00 10 2019-05-17 Acute Graft versus host disease
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable Ended
  2024-513731-24-00 4 2019-05-14 Non-small cell lung cancer (NSCLC)
• Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended
  2022-502187-20-00 5 2019-04-11 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 5 2019-04-09 Hereditary Transthyretin Amyloidosis
• Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended
  2023-508832-68-00 9 2019-03-28 Recurrent or stage IVB cervical cancer
• A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepati … Ended
  2024-512352-38-00 4 2019-03-28 Hepatitis B, Chronic
• Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. Ended
  2023-507777-18-00 4 2019-03-19 Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
• "Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients … Ended
  2023-510020-68-00 7 2019-03-18 Hepatitis B, Chronic
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on … Ended
  2023-509800-14-00 3 2019-02-25 extensive stage small cell lung cancer
• Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended
  2023-507330-24-00 9 2019-02-07 Chronic Graft Versus Host Disease (cGVHD)
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 5 2019-01-25 Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung Cancer Ended
  2022-500990-16-00 4 2018-12-19 Stage IV non-small cell lung cancer
• Olaparib Monotherapy in HRRm or HRD Positive Cancer Ended
  2022-500797-34-00 4 2018-12-17 Treatment of participants with positive cancer for HRRm or HRD.
• Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can … Ended
  2023-508550-25-00 3 2018-12-10 Pre and post-menopausal women with resectable primary breast cancer an
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet … Ended
  2023-507312-13-00 5 2018-11-15 Multiple Myeloma
• A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanc … Ended
  2024-515254-24-00 1 2018-11-08 Previously treated lymphoma (blood cancer) or solid tumors and NHL

Showing 3,265–3,288 of 3,391 trials